Supporting detail

The real-time trial was presented as part of a bigger FDA re-engineering effort

The transcript places the real-time trial inside a larger push to re-engineer more of the drug development and approval process.

pre-INDIRB reformcontinuous trials

Early phase changes were mentioned

Makary said FDA is trying new things in the pre-IND process, reducing routine two-species animal testing, and reducing or deferring some IND requirements.

Connected idea: the agency is looking across the lifecycle.

IRB and trial design changes

The transcript mentions reforming the IRB process and moving away from a default 2:1 pivotal trial structure by allowing Bayesian statistics in some settings.

Connected idea: FDA is also looking at trial design and governance mechanisms.

Post-marketing visibility

Makary said FDA also wants to harness big data, electronic health records, and cloud computing in the post-marketing period to see safety and efficacy quickly after approval.

Connected idea: the modernization theme extends beyond pre-approval trials.

End goal

Across the transcript, the end goal is described as more cures, more meaningful treatments, and less lag throughout the development process.

Connected idea: the trial announcement is one visible piece of a wider campaign.